← Back to patent-cliff list
CAS 109-92-2
[(Ethenyl)oxy]ethaneethoxyethene
Codes: (VII)101438-2-a, (II)169995-16-a, CEVI-012
Application context (from source-drug indications)
Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateContraceptionDrospirenoneStomatitis, aphthousDrospirenonePremenstrual dysphoric disorderDrospirenonePremenstrual syndromeDrospirenoneDysmenorrhoeaDrospirenoneDepressionDrospirenonePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelSjögren's syndromeCevimeline Hydrochloride Hydrate口腔干燥Cevimeline Hydrochloride HydrateRadiation injuryCevimeline Hydrochloride Hydrate口腔疾病Cevimeline Hydrochloride HydrateHead and neck cancerCevimeline Hydrochloride Hydrate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Drospirenone | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
| Cevimeline Hydrochloride Hydrate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(NZ)-4-Methoxy-N-(phenylmethylidene)aniline→(2-Chloranyl-2-oxidanylideneethyl) ethanoate→cis-1-(4-Methoxyphenyl)-2-oxo-4-phenylazetidin-3-yl acetate→cis-2-Oxo-4-phenylazetidin-3-yl acetate→alpha-Chlorobenzaldehyde→(3R,4S)-3-hydroxy-4-phenylazetidin-2-one→[(Ethenyl)oxy]ethane→(3R,4S)-3-(1-Ethoxyethoxy)-4-phenylazetidin-2-one→1-Benzoyl-3(R)-(1-ethoxyethoxy)-4(S)-phenylazetidin-2-one→3(S)-(Benzamido)-2(R)-(1-ethoxyethoxy)-3-phenylpropionic acid→(4S,5R)-5-(1-ethoxyethoxy)-2,4-diphenyl-5,6-dihydro-4H-1,3-oxazin-6-one→(2alpha,5beta,7beta,10beta,13alpha)-4-(Acetyloxy)-1,7,10,13-tetrahydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate→(1S,2S,3R,4S,7R,9R,10S,12R,15S)-4,12-bis(acetyloxy)-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate
(1aR,1bR,5aR,5bS,7aS,8aS,9aS,9bS,9cR,9dR)-1b,3-Dihydroxy-5a,7a-dimethylperhydrocyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-8-one→[(Ethenyl)oxy]ethane→(1aR,5aR,5bS,7aS,8aS,9aS,9bS,9cR,9dR)-3-(1-Ethoxyethoxy)-1b-hydroxy-5a,7a-dimethylperhydrocyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-8-one→3-[(1aR,1bR,5aR,5bS,7aS,8R,8aS,9aS,9bS,9cR,9dR)-3-(1-Ethoxyethoxy)-1b,8-dihydroxy-5a,7a-dimethyloperhydrocyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-8-yl]propanenitrile→3-(5beta,17alpha-Dihydroxy-3-oxo-6beta,7beta:15beta,16beta-dimethyleneandrostan-17-yl)propanenitrile
(NZ)-4-Methoxy-N-(phenylmethylidene)aniline→(2-Chloranyl-2-oxidanylideneethyl) ethanoate→cis-1-(4-Methoxyphenyl)-2-oxo-4-phenylazetidin-3-yl acetate→cis-2-Oxo-4-phenylazetidin-3-yl acetate→alpha-Chlorobenzaldehyde→(3R,4S)-3-hydroxy-4-phenylazetidin-2-one→[(Ethenyl)oxy]ethane→(3R,4S)-3-(1-Ethoxyethoxy)-4-phenylazetidin-2-one→1-Benzoyl-3(R)-(1-ethoxyethoxy)-4(S)-phenylazetidin-2-one→3(S)-(Benzamido)-2(R)-(1-ethoxyethoxy)-3-phenylpropionic acid→(4S,5R)-5-(1-ethoxyethoxy)-2,4-diphenyl-5,6-dihydro-4H-1,3-oxazin-6-one→(2alpha,5beta,7beta,10beta,13alpha)-4-(Acetyloxy)-1,7,10,13-tetrahydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate→(1S,2S,3R,4S,7R,9R,10S,12R,15S)-4,12-bis(acetyloxy)-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.